Delivery Order SPE2DB25D9305-SPE2DB25FQACT
- Not listed
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,292 contract is for the delivery of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a specialized pharmaceutical product, with a performance period ending on February 14, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,780.55 contract is for the delivery of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,561.10 contract is for the delivery of VABYSMO 6 MG/0.05 ML SYRINGE 0.05ML, a specialized pharmaceutical product, with a period of performance through January 15, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,983.44 contract is for the supply of VABYSMO 6 MG/0.05 ML SYRINGE 0.05ML, a pharmaceutical product, with a period of performance through August 6, 2025. DMS Pharmaceutical Group holds a significant Indefinite Delivery Contract (IDC) valued at $499,999,999 with the DLA under the SPE2DB...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $46,683.30, is for the supply of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product. The contract is not set-aside and has an ultimate completion date of February 20, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,983.44, is for the delivery of VABYSMO 6 MG/0.05 ML SYRINGE 0.05ML medical supplies. The contract has an ultimate completion date of May 1, 2025 and was awarded on April 10, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite...
- This is a $6,224.44 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a specialized pharmaceutical product, with a period of performance through November 7, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $29,834.40 and covers the delivery of VABYSMO 6 MG/0.05 ML SYRINGE 0.05ML, a pharmaceutical product, with a period of performance through July 28, 2025. DMS Pharmaceutical Group Inc. is a crucial supplier in the federal pharmaceutical supply chain, holding a significant...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $58,336.00, is for the delivery of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a specialized pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
- This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $46,683.30 award is for the supply of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued at up to $499,999,999 that...
- SPE2DB25D9305Indefinite Delivery Contract
- SPE2DB25D9305-SPE2DB25FQACTDelivery Order
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,916.80, is for the delivery of VABYSMO 6 MG/0.05 ML VIAL 0.05ML, a specialized pharmaceutical product. The contract has an ultimate completion date of March 7, 2025. DMS Pharmaceutical Group Inc. also holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This IDC, which is valid through November 2026, positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 2/13/25 |